Axial Spondyloarthritis | Access & Reimbursement | US | Ankylosing Spondylitis and Non-Radiographic AxSpA | 2020
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and two IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA, which is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs), and their positioning as the first-line targeted agents is encouraged through payer policies. To overcome this challenge, the marketers of Cosentyx, Taltz, and emerging therapies, including UCB’s bimekizumab and Pfizer’s Xeljanz, need to understand how best to navigate the access and reimbursement environment, particularly because payers expect to increase their stringency for this indication in the coming years.
QUESTIONS ANSWERED
- What are the patient-share leaders among AxSpA biologics, and which AxSpA agents do physicians and payers believe perform best on specific clinical and market access factors?
- Are there differences in how payers view the different AxSpA subpopulations? What are the biggest reimbursement obstacles that AxSpA drugs face?
- What are physicians’ perceptions of the emerging agents bimekizumab and Xeljanz, and how do payers anticipate covering these agents?
- What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
